Ethan Thompson

3.1k total citations
51 papers, 728 citations indexed

About

Ethan Thompson is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Ethan Thompson has authored 51 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 20 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Ethan Thompson's work include CAR-T cell therapy research (16 papers), Multiple Myeloma Research and Treatments (15 papers) and Tuberculosis Research and Epidemiology (9 papers). Ethan Thompson is often cited by papers focused on CAR-T cell therapy research (16 papers), Multiple Myeloma Research and Treatments (15 papers) and Tuberculosis Research and Epidemiology (9 papers). Ethan Thompson collaborates with scholars based in United States, Germany and South Africa. Ethan Thompson's co-authors include D. Son, Andreas Karch, Kristan Jensen, Daniel E. Zak, Tatsuo Azeyanagi, Thomas J. Scriba, Gerhard Walzl, Fergal J. Duffy, Stefan H. E. Kaufmann and Sara Suliman and has published in prestigious journals such as Physical Review Letters, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Ethan Thompson

47 papers receiving 718 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ethan Thompson United States	14	188	172	156	154	141	51	728
Sabine Schmidt Germany	17	88 0.5×	345 2.0×	141 0.9×	221 1.4×	65 0.5×	38	1.6k
Kazushi Izawa Japan	16	98 0.5×	270 1.6×	462 3.0×	189 1.2×	139 1.0×	54	953
Rodat T. Cunningham United Kingdom	14	124 0.7×	113 0.7×	231 1.5×	39 0.3×	35 0.2×	21	662
Saili Zhao China	14	103 0.5×	422 2.5×	125 0.8×	31 0.2×	518 3.7×	40	1.1k
A. Shoji Japan	23	83 0.4×	144 0.8×	359 2.3×	14 0.1×	154 1.1×	116	1.6k
Nobuaki Nakano Japan	14	28 0.1×	56 0.3×	170 1.1×	82 0.5×	167 1.2×	55	730
James P. Long United States	22	148 0.8×	441 2.6×	604 3.9×	59 0.4×	226 1.6×	92	1.9k
J.J. Phelan Ireland	25	149 0.8×	526 3.1×	560 3.6×	364 2.4×	221 1.6×	84	1.9k
D. J. Zhou China	20	288 1.5×	133 0.8×	536 3.4×	46 0.3×	65 0.5×	48	1.3k
Wei Ye China	13	44 0.2×	111 0.6×	73 0.5×	124 0.8×	76 0.5×	62	739

Countries citing papers authored by Ethan Thompson

Since Specialization

Citations

This map shows the geographic impact of Ethan Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ethan Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ethan Thompson more than expected).

Fields of papers citing papers by Ethan Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ethan Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ethan Thompson. The network helps show where Ethan Thompson may publish in the future.

Co-authorship network of co-authors of Ethan Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Ethan Thompson. A scholar is included among the top collaborators of Ethan Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ethan Thompson. Ethan Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bewersdorf, Jan Philipp, Rory M. Shallis, Ethan Thompson, et al.. (2025). Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab. Therapeutic Advances in Hematology. 16. 1584265104–1584265104.

Paiva, Bruno, Irene Manrique, Ethan Thompson, et al.. (2024). Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients. Blood. 144(Supplement 1). 900–900. 1 indexed citations

Zeidan, Amer M., Jan Philipp Bewersdorf, Rory M. Shallis, et al.. (2024). Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine. Therapeutic Advances in Hematology. 15. 1574175664–1574175664. 8 indexed citations

Gangurde, Sunil S., Ethan Thompson, Yaduru Shasidhar, et al.. (2024). Linkage Mapping and Genome-Wide Association Study Identified Two Peanut Late Leaf Spot Resistance Loci, PLLSR-1 and PLLSR-2, Using Nested Association Mapping. Phytopathology. 114(6). 1346–1355. 2 indexed citations

Leleu, Xavier, Alfred Chung, Noopur Raje, et al.. (2024). P-045 Idecabtagene Vicleucel (ide-cel) in Patients (pts) With Clinical High-Risk Early Relapse Multiple Myeloma (MM) Without Front-Line (1L) Autologous Stem Cell Transplantation (ASCT): KarMMA-2 Cohort 2B. Clinical Lymphoma Myeloma & Leukemia. 24. S67–S67. 1 indexed citations

Tang, Hao, Minshi Wang, Fan Wu, et al.. (2024). Cross-Cohort Correlative Analysis of Clinically High-Risk Patients (pts) Treated with Idecabtagene Vicleucel (ide-cel) in KarMMa-2: Association between Progression-Free Survival (PFS) and Tumor Burden and Immune Status at Apheresis. Blood. 144(Supplement 1). 3382–3382.

Piasecki, Julia, Keyur Desai, Ethan Thompson, et al.. (2023). P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e7421475–e7421475. 1 indexed citations

Piasecki, Julia, Keyur Desai, Ethan Thompson, et al.. (2023). Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 41(16_suppl). 8031–8031. 2 indexed citations

Meier, Stuart, James A. Seddon, Elizna Maasdorp, et al.. (2022). Neutrophil degranulation, NETosis and platelet degranulation pathway genes are co-induced in whole blood up to six months before tuberculosis diagnosis. PLoS ONE. 17(12). e0278295–e0278295. 8 indexed citations

10.

Zeidan, Amer M., Jan Philipp Bewersdorf, Rory M. Shallis, et al.. (2022). Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia. 37(1). 240–243. 10 indexed citations

11.

Odia, Trust, Stephanus T. Malherbe, Stuart Meier, et al.. (2021). The Peripheral Blood Transcriptome Is Correlated With PET Measures of Lung Inflammation During Successful Tuberculosis Treatment. Frontiers in Immunology. 11. 596173–596173. 8 indexed citations

12.

Young, Mary H., Elizabeth Whalen, Wilbert B. Copeland, et al.. (2021). Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. Scientific Reports. 11(1). 16460–16460. 5 indexed citations

13.

Du, Ying, Ethan Thompson, Julius Müller, et al.. (2020). The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection. Frontiers in Immunology. 11. 669–669. 7 indexed citations

14.

Penn‐Nicholson, Adam, Thomas Hraha, Ethan Thompson, et al.. (2019). Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study. PLoS Medicine. 16(4). e1002781–e1002781. 68 indexed citations

15.

Duffy, Fergal J., Ethan Thompson, Thomas J. Scriba, & Daniel E. Zak. (2019). Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state. PLoS ONE. 14(7). e0219322–e0219322. 16 indexed citations

16.

Duffy, Fergal J., January Weiner, Scott G. Hansen, et al.. (2019). Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome. Frontiers in Immunology. 10. 527–527. 37 indexed citations

17.

Duffy, Fergal J., Ethan Thompson, Katrina Downing, et al.. (2018). A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts. Frontiers in Immunology. 9. 661–661. 36 indexed citations

18.

Fioré-Gartland, Andrew, Lindsay N. Carpp, Kogieleum Naidoo, et al.. (2017). Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention. Tuberculosis. 109. 61–68. 19 indexed citations

19.

Thompson, Ethan & Timothy Galitski. (2012). Quantifying and Analyzing the Network Basis of Genetic Complexity. PLoS Computational Biology. 8(7). e1002583–e1002583. 5 indexed citations

20.

Floreani, Anthony A., Todd A. Wyatt, Julie A. Stoner, et al.. (2003). Smoke and C5a Induce Airway Epithelial Intercellular Adhesion Molecule-1 and Cell Adhesion. American Journal of Respiratory Cell and Molecular Biology. 29(4). 472–482. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact